These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 28199021)
1. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia). Elliott JW; Swinbourne F; Parry A; Baines L J Small Anim Pract; 2017 Jul; 58(7):416-418. PubMed ID: 28199021 [TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656 [TBL] [Abstract][Full Text] [Related]
3. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis. Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546 [TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018. Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932 [TBL] [Abstract][Full Text] [Related]
5. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation. Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134 [TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation. Irie M; Takeuchi Y; Ohtake Y; Suzuki H; Nagata N; Miyoshi T; Kagawa Y; Yamagami T J Vet Med Sci; 2015 Nov; 77(11):1535-9. PubMed ID: 26074249 [TBL] [Abstract][Full Text] [Related]
7. [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652 [No Abstract] [Full Text] [Related]
8. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739 [TBL] [Abstract][Full Text] [Related]
9. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs. Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719 [TBL] [Abstract][Full Text] [Related]
10. Successful post-incomplete resection management of gastrointestinal stromal tumor using imatinib based on adenosine triphosphate-based tumor sensitivity assay in a dog. Woo IS; Kim YR; Kim SW; Choi JY; Yoon HY; Bae K; Yoon KA; Kim JH Can Vet J; 2024 Jun; 65(6):553-558. PubMed ID: 38827592 [TBL] [Abstract][Full Text] [Related]
11. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Chon E; McCartan L; Kubicek LN; Vail DM Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041 [TBL] [Abstract][Full Text] [Related]
13. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine. Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175 [TBL] [Abstract][Full Text] [Related]
16. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684 [TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study. Wouda RM; Hocker SE; Higginbotham ML Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187 [TBL] [Abstract][Full Text] [Related]
18. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma. Musser ML; Johannes CM BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474 [TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study. Pan X; Tsimbas K; Kurzman ID; Vail DM Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385 [TBL] [Abstract][Full Text] [Related]